| BRIEF REVIEW |
|
| Year : 2017 | Volume
: 6
| Issue : 1 | Page : 24-26 |
|
|
Hypertension management: Old drug revisited - Cilnidipine
Soumitra Kumar MD, DM
Professor and Head, Department of Cardiology, Vivekananda Institute of Medical Sciences, Kolkata, West Bengal, India
Correspondence Address:
Soumitra Kumar
58/1, Ballygunge Circular Road, Flat - 52B, Kolkata - 700 019, West Bengal
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2250-3528.196653
|
|
|
Cilnidipine is a promising fourth-generation calcium channel blocker which along with inhibition of the L-type Ca 2+ channels in vascular smooth muscle cells, also inhibits the N-type Ca 2+ channels in sympathetic neurons. As a result, in addition to hypotensive action secondary to vascular relaxation, it also demonstrates significant sympatholytic action, whereby it attenuates platelet activation (and consequent arterial thrombosis), tachycardia, oxidative stress, and also inhibits activation of renin-angiotensin system in blood vessels. By virtue of the latter effect, they relieve constriction of postglomerular vessels and thereby ameliorate glomerular hypertension and render renoprotective effect. Besides these, cilnidipine also improves insulin resistance, nitric oxide production, and protects against retinal neuronal injury. Thus, it is expected to be a very useful addition in the current armamentarium for the treatment of hypertension. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
